Leverage Unique Glioblastoma Ex Vivo Models to Advance Your Drug Discovery
As reported by the Glioblastoma Foundation, the average life expectancy for glioblastoma patients who undergo treatment is 12-15 months and only four months for those who do not receive treatment. This poor prognosis means that there is a huge unmet need for people diagnosed with this disease.
For researchers in this space, our new ex vivo screen offers you with the opportunity to test your therapeutic across a curated panel of 11 glioblastoma patient-derived tumor models. These low-passage models are derived from our highly annotated PDX bank, offering unparalleled translational relevance for preclinical research.
-
Clinically Relevant ModelsA curated panel of low-passage ex vivo models derived from patient tumors for superior translational relevance.
-
Flexible, High-Throughput ScreeningAvailable in both 96-well plate format, enabling efficient screening of multiple test agents per run.
-
Translational Multi-omics
Matched clinical histories, WES, RNAseq, proteomics, and biomarker data available through Lumin for deeper insights.. -
No Minimum EnrollmentChoose 1-11 models, with one reference arm, temsirolimus, offered in each screen.
Glioblastoma Ex Vivo Screen Models
11 clinically relevant glioblastoma low-passage ex vivo models
|
Models
|
Recommended cell seeding density
|
Day of 3D-structure formation
|
Proliferation rate > 1 and P < 0.05 at day 4?
|
|---|---|---|---|
|
CTG-0667 (28OCT2024)
|
5000
|
3
|
No
|
|
CTG-2258 (19NOV2024)
|
5000
|
3
|
No
|
|
CTG-2687 (01JUL2024)
|
1250
|
3
|
Yes
|
|
CTG-2816 (05SEP2024)
|
2500
|
3
|
No
|
|
CTG-2860 (02JAN2025)
|
5000
|
3
|
No
|
|
CTG-2879 (26JUN2024)
|
5000
|
3
|
Yes
|
|
CTG-3039 (25FEB2025)
|
5000
|
3
|
No
|
|
CTG-3153 (27FEB2025)
|
5000
|
3
|
No
|
|
CTG-3300 (16OCT2024)
|
2500
|
3
|
Yes
|
|
CTG-3307 (29AUG2024)
|
5000
|
3
|
No
|
|
CTG-3141 (06MAR2025)
|
2500
|
3
|
No
|